| Year |
Citation |
Score |
| 2023 |
Biswas S, Mandal G, Anadon CM, Chaurio RA, Lopez-Bailon LU, Nagy MZ, Mine JA, Hänggi K, Sprenger KB, Innamarato P, Harro CM, Powers JJ, Johnson J, Fang B, Eysha M, ... ... Curiel TJ, et al. Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. Immunity. PMID 37909039 DOI: 10.1016/j.immuni.2023.09.013 |
0.35 |
|
| 2023 |
Ontiveros CO, Murray CE, Crossland G, Curiel TJ. Considerations and Approaches for Cancer Immunotherapy in the Aging Host. Cancer Immunology Research. OF1-OF13. PMID 37769157 DOI: 10.1158/2326-6066.CIR-23-0121 |
0.336 |
|
| 2023 |
Bai H, Padron AS, Deng Y, Liao YJ, Murray CJ, Ontiveros C, Kari SJ, Kancharla A, Kornepati AVR, Garcia M, Reyes RM, Gupta HB, Conejo-Garcia JR, Curiel T. Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects. Journal For Immunotherapy of Cancer. 11. PMID 36759012 DOI: 10.1136/jitc-2022-004871 |
0.355 |
|
| 2022 |
Garcia MG, Deng Y, Murray C, Reyes RM, Padron A, Bai H, Kancharla A, Gupta H, Shen-Orr S, Curiel TJ. Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. Aging and Cancer. 3: 68-83. PMID 36876140 DOI: 10.1002/aac2.12045 |
0.308 |
|
| 2022 |
Hong J, Lee JH, Zhang Z, Wu Y, Yang M, Liao Y, de la Rosa R, Scheirer J, Pechacek D, Zhang N, Xu Z, Curiel T, Tan X, Huang TH, Xu K. PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer. Cancer Research. PMID 36222718 DOI: 10.1158/0008-5472.CAN-22-0736 |
0.332 |
|
| 2022 |
Murray C, Galvan E, Ontiveros C, Deng Y, Bai H, Padron AS, Hinchee-Rodriguez K, Garcia MG, Kornepati A, Conejo-Garcia J, Curiel TJ. Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents. International Journal of Molecular Sciences. 23. PMID 35563520 DOI: 10.3390/ijms23095129 |
0.31 |
|
| 2022 |
Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM, Mine JA, Sprenger KB, Cortina C, Powers JJ, Costich TL, ... ... Curiel TJ, et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. PMID 35427494 DOI: 10.1016/j.ccell.2022.03.008 |
0.418 |
|
| 2022 |
Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, Moran C, Ortiz AC, Cortina C, Rigolizzo KE, Sprenger KB, Mine JA, Innamarato P, Mandal G, Powers JJ, ... ... Curiel TJ, et al. TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity. 55: 115-128.e9. PMID 35021053 DOI: 10.1016/j.immuni.2021.12.007 |
0.375 |
|
| 2021 |
Mandal G, Biswas S, Anadon CM, Yu X, Gatenbee CD, Prabhakaran S, Payne KK, Chaurio RA, Martin A, Innamarato P, Moran C, Powers JJ, Harro CM, Mine JA, Sprenger KB, ... ... Curiel TJ, et al. IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer. Cancer Research. PMID 34949671 DOI: 10.1158/0008-5472.CAN-21-2376 |
0.378 |
|
| 2021 |
Ji N, Mukherjee N, Shu ZJ, Reyes RM, Meeks JJ, McConkey DJ, Gelfond JA, Curiel TJ, Svatek RS. γδ T cells support antigen-specific αβ T cell-mediated antitumor responses during BCG treatment for bladder cancer. Cancer Immunology Research. PMID 34607803 DOI: 10.1158/2326-6066.CIR-21-0285 |
0.44 |
|
| 2021 |
Molodtsov AK, Khatwani N, Vella JL, Lewis KA, Zhao Y, Han J, Sullivan DE, Searles TG, Preiss NK, Shabaneh TB, Zhang P, Hawkes AR, Malik BT, Kolling FW, Usherwood EJ, ... ... Curiel TJ, et al. Resident memory CD8 T cells in regional lymph nodes mediate immunity to metastatic melanoma. Immunity. 54: 2117-2132.e7. PMID 34525340 DOI: 10.1016/j.immuni.2021.08.019 |
0.348 |
|
| 2021 |
Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, Gupta HB, Padron AS, Kancharla A, Zhang C, Garcia M, Kornepati AVR, Boyman O, Conejo-Garcia JR, Svatek RS, ... Curiel TJ, et al. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. Journal For Immunotherapy of Cancer. 9. PMID 33849925 DOI: 10.1136/jitc-2020-002051 |
0.304 |
|
| 2021 |
Thibodeaux S, Barnett B, Pandeswara S, Wall S, Hurez V, Dao V, Sun L, Daniel B, Brumlik MJ, Drerup JM, Padron A, Whiteside TL, Kryczek I, Zou W, Curiel TJ. Interferon-α augments clinical efficacy of regulatory T cell depletion with denileukin diftitox in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33771857 DOI: 10.1158/1078-0432.CCR-20-4594 |
0.732 |
|
| 2021 |
Ji N, Mukherjee N, Reyes RM, Gelfond J, Javors M, Meeks JJ, McConkey DJ, Shu ZJ, Ramamurthy C, Dennett R, Curiel TJ, Svatek RS. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. Journal For Immunotherapy of Cancer. 9. PMID 33653802 DOI: 10.1136/jitc-2020-001941 |
0.307 |
|
| 2021 |
Yuan B, Clark CA, Wu B, Yang J, Drerup JM, Li T, Jin VX, Hu Y, Curiel TJ, Li R. Estrogen receptor beta signaling in CD8 T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch. Journal For Immunotherapy of Cancer. 9. PMID 33462142 DOI: 10.1136/jitc-2020-001932 |
0.407 |
|
| 2020 |
Drerup JM, Deng Y, Pandeswara SL, Padrón ÁS, Reyes RM, Zhang X, Mendez J, Liu A, Clark CA, Chen W, Conejo-Garcia JR, Hurez V, Gupta H, Curiel TJ. CD122-selective IL-2 complexes reduce immunosuppression, promote Treg fragility, and sensitize tumor response to PD-L1 blockade. Cancer Research. PMID 32948605 DOI: 10.1158/0008-5472.Can-20-0002 |
0.38 |
|
| 2020 |
Wu B, Chiang HC, Sun X, Yuan B, Mitra P, Hu Y, Curiel TJ, Li R. Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. Journal For Immunotherapy of Cancer. 8. PMID 32817394 DOI: 10.1136/Jitc-2020-000964 |
0.33 |
|
| 2020 |
Wu B, Sun X, Yuan B, Ge F, Gupta HB, Chiang HC, Li J, Hu Y, Curiel TJ, Li R. PPARγ inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner. International Journal of Biological Sciences. 16: 1526-1535. PMID 32226299 DOI: 10.7150/Ijbs.42966 |
0.337 |
|
| 2020 |
Yan H, Viswanadhapalli S, Chupp D, Fernandez M, Wu S, Wang J, Moroney J, Taylor J, Im J, Rivera C, Luo Y, Liu J, Sareddy G, Curiel T, Casali P, et al. Abstract P5-04-05: Tumor-infiltrating B lymphocytes produce IL-27 to upregulate PD-L1 expression in the tumor microenvironment and promote breast cancer progression Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-04-05 |
0.419 |
|
| 2020 |
Yan H, Viswanadhapalli S, Perez D, Chupp D, Fernandez M, Wang J, Wu S, Rivera CE, Moroney JB, Taylor J, Im J, Luo Y, Liu J, Gangadhara S, Curiel T, et al. Abstract 2654: B cells produce IL-27 in breast cancer to upregulate PD-L1 expression and promote tumor progression Tumor Biology. DOI: 10.1158/1538-7445.Am2020-2654 |
0.369 |
|
| 2019 |
Ji N, Mukherjee N, Morales EE, Tomasini ME, Hurez V, Curiel TJ, Abate G, Hoft DF, Zhao XR, Gelfond J, Maiti S, Cooper LJN, Svatek RS. Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial. Oncoimmunology. 8: 1614857. PMID 31413921 DOI: 10.1080/2162402X.2019.1614857 |
0.485 |
|
| 2018 |
Svatek RS, Ji N, de Leon EMB, Mukherjee N, Kabra A, Hurez V, Nicolas M, Michalek JE, Javors M, Wheeler K, Sharp ZD, Livi CB, Shu ZJ, Henkes DN, Curiel TJ. Rapamycin prevents surgery-induced immune dysfunction in patients with bladder cancer. Cancer Immunology Research. PMID 30563829 DOI: 10.1158/2326-6066.Cir-18-0336 |
0.487 |
|
| 2018 |
Mukherjee N, Ji N, Hurez V, Curiel TJ, Montgomery MO, Braun AJ, Nicolas M, Aguilera M, Kaushik D, Liu Q, Ruan J, Kendrick KA, Svatek RS. Intratumoral CD56 natural killer cells are associated with improved survival in bladder cancer. Oncotarget. 9: 36492-36502. PMID 30559932 DOI: 10.18632/Oncotarget.26362 |
0.414 |
|
| 2018 |
Wu B, Sun X, Gupta HB, Yuan B, Li J, Ge F, Chiang HC, Zhang X, Zhang C, Zhang D, Yang J, Hu Y, Curiel TJ, Li R. Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. Oncoimmunology. 7: e1500107. PMID 30393583 DOI: 10.1080/2162402X.2018.1500107 |
0.303 |
|
| 2018 |
Shabaneh TB, Molodtsov A, Steinberg SM, Zhang P, Torres GM, Mohamed GA, Boni A, Curiel TJ, Angeles CV, Turk MJ. Oncogenic BRAFV600E governs regulatory T cell recruitment during melanoma tumorigenesis. Cancer Research. PMID 30026331 DOI: 10.1158/0008-5472.Can-18-0365 |
0.481 |
|
| 2018 |
Padrón Á, Hurez V, Gupta HB, Clark CA, Pandeswara SL, Yuan B, Svatek RS, Turk MJ, Drerup JM, Li R, Curiel TJ. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. Experimental Gerontology. PMID 29326088 DOI: 10.1016/J.Exger.2017.12.025 |
0.412 |
|
| 2018 |
Sun X, Gupta K, Wu B, Zhang D, Yuan B, Zhang X, Chiang HC, Zhang C, Curiel TJ, Bendeck MP, Hursting S, Hu Y, Li R. Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulatingadipose stromal interleukin 6 production in mice. The Journal of Biological Chemistry. PMID 29298894 DOI: 10.1074/Jbc.Ra117.000672 |
0.397 |
|
| 2018 |
Mukherjee N, Ji N, Tomasini ME, Hurez V, Curiel TJ, Montgomery MO, Braun AJ, Nicolas M, Flores MA, Liu Q, Ruan J, Svatek RS. Abstract 3792: Intratumoral CD56brightnatural killer cells are associated with improved survival in bladder cancer Immunology. DOI: 10.1158/1538-7445.Am2018-3792 |
0.37 |
|
| 2017 |
Hurez V, Padrón Á, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Experimental Gerontology. PMID 28987644 DOI: 10.1016/J.Exger.2017.10.002 |
0.429 |
|
| 2017 |
Liu J, Viswanadhapalli S, Garcia L, Zhou M, Nair BC, Kost E, Tekmal RR, Li R, Rao MK, Curiel T, Vadlamudi RK, Sareddy GR. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer. Oncotarget. PMID 28654894 DOI: 10.18632/Oncotarget.18442 |
0.431 |
|
| 2017 |
Clark CA, Gupta HB, Curiel TJ. Tumor cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with clinical potential. Autophagy. 1-2. PMID 28368722 DOI: 10.1080/15548627.2017.1280223 |
0.448 |
|
| 2017 |
Downs-Canner S, Berkey S, Delgoffe GM, Edwards RP, Curiel T, Odunsi K, Bartlett DL, Obermajer N. Suppressive IL-17A(+)Foxp3(+) and ex-Th17 IL-17A(neg)Foxp3(+) Treg cells are a source of tumour-associated Treg cells. Nature Communications. 8: 14649. PMID 28290453 DOI: 10.1038/Ncomms14649 |
0.353 |
|
| 2017 |
Steinberg SM, Shabaneh T, Zhang P, Martyanov V, Li Z, Malik B, Wood T, Boni A, Molodtsov A, Angeles CV, Curiel TJ, Whitfield M, Turk MJ. Myeloid cells that impair immunotherapy are restored in melanomas which acquire resistance to BRAF inhibitors. Cancer Research. PMID 28202513 DOI: 10.1158/0008-5472.Can-16-1755 |
0.41 |
|
| 2017 |
Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS, Hurez V, Garcia J, Vadlamudi R, Li R, Curiel TJ. Abstract 5649: Cell-intrinsic PD-L1 directs tumor initiating cell fate and rapamycin and interferon-γ response Cancer Research. 77: 5649-5649. DOI: 10.1158/1538-7445.Am2017-5649 |
0.351 |
|
| 2017 |
Clark CA, Gupta HB, Padron A, Zhang D, Hurez V, Turk MJ, Li R, Curiel T. Abstract 3696: Tumor-intrinsic PD-L1 alters tumor chemokines, NK cell trafficking and function, and renders distant PD-L1 null tumors responsive to αPD-L1 Cancer Research. 77: 3696-3696. DOI: 10.1158/1538-7445.Am2017-3696 |
0.343 |
|
| 2017 |
Drerup JM, Pandeswara SL, Liu A, Clark CA, Padron AS, Chen W, Hurez V, Curiel TJ. Abstract 1608: CD122-selective IL-2/anti-IL-2 complexes reduce regulatory T cell function and promote CD8+ T cell polyfunctionality for durable ovarian cancer immunotherapy Cancer Research. 77: 1608-1608. DOI: 10.1158/1538-7445.Am2017-1608 |
0.409 |
|
| 2017 |
Ji N, Morales EE, Mukherjee N, Hurez V, Curiel TJ, Abate G, Hoft DF, Svatek RS. PD48-06 2 YEAR CLINICAL AND IMMUNOLOGIC OUTCOMES OF INTRADERMAL BCG PRIMING PRIOR TO INTRAVESICAL INDUCTION IMMUNOTHERAPY FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2354 |
0.3 |
|
| 2016 |
Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS, Hurez V, Conejo-Garcia J, Vadlamudi R, Li R, Curiel TJ. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduction and Targeted Therapy. 1. PMID 28798885 DOI: 10.1038/Sigtrans.2016.30 |
0.415 |
|
| 2016 |
Liu Y, Pandeswara S, Dao V, Padrón Á, Drerup JM, Lao S, Liu A, Hurez V, Curiel TJ. Biphasic rapamycin effects in lymphoma and carcinoma treatment. Cancer Research. PMID 27737881 DOI: 10.1158/0008-5472.Can-16-1140 |
0.508 |
|
| 2016 |
Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, Nguyen JM, Curiel TJ, Cadungog MG, Singhal S, Eruslanov EB, Zhang P, Tchou J, Zhang R, Conejo-Garcia JR. Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Supressor Cells. Cancer Discovery. PMID 27694385 DOI: 10.1158/2159-8290.Cd-16-0502 |
0.441 |
|
| 2016 |
Hurez V, Padrón Á, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Clinical and Experimental Immunology. PMID 27690272 DOI: 10.1111/Cei.12875 |
0.429 |
|
| 2016 |
Clark CA, Gupta H, Sareddy GR, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia JR, Murthy K, Liu Y, Turk MJ, Thedieck K, Hurez V, Li R, ... ... Curiel TJ, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma. Cancer Research. PMID 27671674 DOI: 10.1158/0008-5472.Can-16-0258 |
0.349 |
|
| 2016 |
Dao V, Liu Y, Pandeswara S, Svatek RS, Gelfond JA, Liu A, Hurez V, Curiel TJ. Immune stimulatory effects of rapamycin are mediated by stimulation of antitumor γδ T cells. Cancer Research. PMID 27569211 DOI: 10.1158/0008-5472.Can-16-0091 |
0.525 |
|
| 2016 |
Patel S, Hurez V, Nawrocki ST, Goros M, Michalek J, Sarantopoulos J, Curiel T, Mahalingam D. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. Oncotarget. PMID 27463016 DOI: 10.18632/Oncotarget.10824 |
0.514 |
|
| 2016 |
Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK, Wickramasinghe J, Nguyen JM, O'Brien SW, Gumireddy K, Huang Q, Cadungog M, Connolly DC, Tchou J, Curiel TJ, et al. FOLLICLE-STIMULATING HORMONE RECEPTOR IS EXPRESSED BY MOST OVARIAN CANCER SUBTYPES AND IS A SAFE AND EFFECTIVE IMMUNOTHERAPEUTIC TARGET. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27435394 DOI: 10.1158/1078-0432.Ccr-16-0492 |
0.386 |
|
| 2016 |
Yuan B, Cheng L, Gupta K, Chiang HC, Gupta HB, Sareddy GR, Wang D, Lathrop K, Elledge R, Wang P, McHardy S, Vadlamudi R, Curiel TJ, Hu Y, Ye Q, et al. Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer. Oncotarget. PMID 27323858 DOI: 10.18632/Oncotarget.10018 |
0.392 |
|
| 2016 |
Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27269937 DOI: 10.1200/Jco.2016.67.9761 |
0.35 |
|
| 2016 |
Patel SR, Hurez V, Nawrocki ST, Goros M, Michalek J, Sarantopoulos J, Curiel TJ, Mahalingam D. Effect of vorinostat (VOR) and hydroxychloroquine (HCQ) on immunity and autophagy in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 34: 670-670. DOI: 10.1200/Jco.2016.34.4_Suppl.670 |
0.459 |
|
| 2016 |
Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke JJ, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Kurland J, Rebelatto MC, Jin X, et al. Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer. Journal of Clinical Oncology. 34: 4502-4502. DOI: 10.1200/Jco.2016.34.15_Suppl.4502 |
0.306 |
|
| 2016 |
Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, ... ... Curiel T, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0173-6 |
0.316 |
|
| 2015 |
Hurez V, Dao V, Liu A, Pandeswara S, Gelfond J, Sun L, Bergman M, Orihuela CJ, Galvan V, Padrón Á, Drerup J, Liu Y, Hasty P, Sharp ZD, Curiel TJ. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. Aging Cell. PMID 26315673 DOI: 10.1111/Acel.12380 |
0.464 |
|
| 2015 |
Christy B, Demaria M, Campisi J, Huang J, Jones D, Dodds SG, Williams C, Hubbard G, Livi CB, Gao X, Weintraub S, Curiel T, Sharp ZD, Hasty P. p53 and rapamycin are additive. Oncotarget. PMID 26158292 DOI: 10.18632/Oncotarget.4602 |
0.344 |
|
| 2015 |
Dao V, Pandeswara S, Liu Y, Hurez V, Dodds S, Callaway D, Liu A, Hasty P, Sharp ZD, Curiel TJ. Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage. Cancer Prevention Research (Philadelphia, Pa.). 8: 400-9. PMID 25736275 DOI: 10.1158/1940-6207.Capr-14-0313-T |
0.39 |
|
| 2015 |
Drerup JM, Liu Y, Padron AS, Murthy K, Hurez V, Zhang B, Curiel TJ. Immunotherapy for ovarian cancer. Current Treatment Options in Oncology. 16: 317. PMID 25648541 DOI: 10.1007/S11864-014-0317-1 |
0.387 |
|
| 2015 |
Chen S, Wang L, Fan J, Ye C, Dominguez D, Zhang Y, Curiel TJ, Fang D, Kuzel TM, Zhang B. Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Research. 75: 519-31. PMID 25502838 DOI: 10.1158/0008-5472.Can-14-2331 |
0.332 |
|
| 2015 |
Kabra A, Leon EMd, Livi C, Javors M, Nicolas M, Henkes D, Sharp D, Curiel T, Svatek R. Mp65-08 A Pharmacodynamic Phase 0/I Study Of Oral Rapamycin In Patients Undergoing Radical Cystectomy For Bladder Cancer The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2298 |
0.301 |
|
| 2014 |
Yuan B, Cheng L, Chiang HC, Xu X, Han Y, Su H, Wang L, Zhang B, Lin J, Li X, Xie X, Wang T, Tekmal RR, Curiel TJ, Yuan ZM, et al. A phosphotyrosine switch determines the antitumor activity of ERβ. The Journal of Clinical Investigation. 124: 3378-90. PMID 24960160 DOI: 10.1172/Jci74085 |
0.39 |
|
| 2014 |
Hasty P, Livi CB, Dodds SG, Jones D, Strong R, Javors M, Fischer KE, Sloane L, Murthy K, Hubbard G, Sun L, Hurez V, Curiel TJ, Sharp ZD. eRapa restores a normal life span in a FAP mouse model. Cancer Prevention Research (Philadelphia, Pa.). 7: 169-78. PMID 24282255 DOI: 10.1158/1940-6207.Capr-13-0299 |
0.389 |
|
| 2014 |
Thibodeaux S, Hurez V, Wall S, Pandeswara S, Daniel B, Liu A, Sun L, Wood L, Zou W, Curiel T. Abstract LB-259: Interferon-α enhances clinical benefits of regulatory T cell depletion in ovarian cancer through direct T cell effects and by inducing bystander IL-6 Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-259 |
0.756 |
|
| 2014 |
Dao V, Pandeswara SL, Cardenas K, Hurez V, Dodds S, Liu Y, Liu A, Dave Sharp Z, Hasty P, Curiel TJ. 35 Cytokine. 70: 36. DOI: 10.1016/J.Cyto.2014.07.042 |
0.492 |
|
| 2013 |
Tomihara K, Curiel TJ, Zhang B. Optimization of immunotherapy in elderly cancer patients. Critical Reviews in Oncogenesis. 18: 573-83. PMID 24579736 DOI: 10.1615/Critrevoncog.2013010591 |
0.422 |
|
| 2013 |
Brumlik MJ, Pandeswara S, Ludwig SM, Jeansonne DP, Lacey MR, Murthy K, Daniel BJ, Wang RF, Thibodeaux SR, Church KM, Hurez V, Kious MJ, Zhang B, Alagbala A, Xia X, ... Curiel TJ, et al. TgMAPK1 is a Toxoplasma gondii MAP kinase that hijacks host MKK3 signals to regulate virulence and interferon-γ-mediated nitric oxide production. Experimental Parasitology. 134: 389-99. PMID 23541881 DOI: 10.1016/J.Exppara.2013.03.016 |
0.667 |
|
| 2013 |
Wang L, Fan J, Chen S, Zhang Y, Curiel TJ, Zhang B. Graft-versus-host disease is enhanced by selective CD73 blockade in mice. Plos One. 8: e58397. PMID 23520507 DOI: 10.1371/Journal.Pone.0058397 |
0.334 |
|
| 2013 |
Hasty P, Sharp ZD, Curiel TJ, Campisi J. mTORC1 and p53: clash of the gods? Cell Cycle (Georgetown, Tex.). 12: 20-5. PMID 23255104 DOI: 10.4161/Cc.22912 |
0.325 |
|
| 2013 |
Mita MM, Mahalingam D, Sarantopoulos J, Amaravadi R, Mita A, Curiel T, Nawrocki S, Giles F, Carew J. Abstract 1686: A Phase 1 dose escalation study to establish the maximum tolerated dose (MTD), pharmacokinetic (PK) and pharmacodynamic (PD) parameters of hydroxychloroquine (HCQ) in combination with vorinostat (V) in patients with advanced solid tumors - final results. Cancer Research. 73: 1686-1686. DOI: 10.1158/1538-7445.Am2013-1686 |
0.361 |
|
| 2013 |
Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P. Erratum: Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis (Clinical Cancer Research (2011) 17 (2250-9)) Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ccr-13-0240 |
0.37 |
|
| 2013 |
Dao V, Hurez V, Pandeswara SL, Sun L, Liu A, Hasty P, Sharp D, Curiel TJ. 60 Cytokine. 63: 257. DOI: 10.1016/J.Cyto.2013.06.063 |
0.483 |
|
| 2013 |
Mahalingam D, Brumlik MJ, Waehler R, Curiel DT, Curiel TJ. Targeted toxins in cancer immunotherapy Cancer Immunotherapy: Paradigms, Practice and Promise. 2147483647: 377-396. DOI: 10.1007/978-1-4614-4732-0_12 |
0.386 |
|
| 2013 |
Mahalingam D, Curiel TJ. Antibodies as Cancer Immunotherapy Springer: New York. 335-376. DOI: 10.1007/978-1-4614-4732-0_11 |
0.394 |
|
| 2012 |
Collins-Burow BM, Antoon JW, Frigo DE, Elliott S, Weldon CB, Boue SM, Beckman BS, Curiel TJ, Alam J, McLachlan JA, Burow ME. Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. The Journal of Steroid Biochemistry and Molecular Biology. 132: 186-93. PMID 22634477 DOI: 10.1016/J.Jsbmb.2012.05.004 |
0.3 |
|
| 2012 |
Hurez V, Daniel BJ, Sun L, Liu AJ, Ludwig SM, Kious MJ, Thibodeaux SR, Pandeswara S, Murthy K, Livi CB, Wall S, Brumlik MJ, Shin T, Zhang B, Curiel TJ. Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Research. 72: 2089-99. PMID 22496463 DOI: 10.1158/0008-5472.Can-11-3019 |
0.725 |
|
| 2012 |
Curiel TJ. Immunotherapy: a useful strategy to help combat multidrug resistance. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 15: 106-13. PMID 22483359 DOI: 10.1016/J.Drup.2012.03.003 |
0.442 |
|
| 2012 |
Sun L, Hurez VJ, Thibodeaux SR, Kious MJ, Liu A, Lin P, Murthy K, Pandeswara S, Shin T, Curiel TJ. Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells. Aging Cell. 11: 509-19. PMID 22372596 DOI: 10.1111/J.1474-9726.2012.00812.X |
0.42 |
|
| 2012 |
Ménétrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W. Targeting regulatory T cells. Targeted Oncology. 7: 15-28. PMID 22327882 DOI: 10.1007/S11523-012-0208-Y |
0.553 |
|
| 2012 |
Tomihara K, Shin T, Hurez VJ, Yagita H, Pardoll DM, Zhang B, Curiel TJ, Shin T. Aging-associated B7-DC+ B cells enhance anti-tumor immunity via Th1 and Th17 induction. Aging Cell. 11: 128-38. PMID 22044484 DOI: 10.1111/J.1474-9726.2011.00764.X |
0.403 |
|
| 2012 |
Mahalingam D, Mita MM, Sarantopoulos J, Wood L, Mita AC, Curiel TJ, Argiris A, Nawrocki ST, Carew JS, Giles FJ. Inhibition of autophagy: Phase I safety, tolerability, and pharmacokinetics (PK) of hydroxychloroquine (H) in combination with vorinostat (V) in patients with advanced solid tumors. Journal of Clinical Oncology. 30: 3073-3073. DOI: 10.1200/Jco.2012.30.15_Suppl.3073 |
0.326 |
|
| 2011 |
Thibodeaux SR, Curiel TJ. Immune therapy for ovarian cancer: promise and pitfalls. International Reviews of Immunology. 30: 102-19. PMID 21557637 DOI: 10.3109/08830185.2011.567361 |
0.391 |
|
| 2011 |
Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. The Journal of Clinical Investigation. 121: 2371-82. PMID 21537079 DOI: 10.1172/Jci45559 |
0.465 |
|
| 2011 |
Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2250-9. PMID 21421858 DOI: 10.1158/1078-0432.Ccr-10-2718 |
0.387 |
|
| 2011 |
Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, ... ... Curiel TJ, et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Research. 71: 603-13. PMID 21123450 DOI: 10.1158/0008-5472.Can-10-3185 |
0.352 |
|
| 2010 |
Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, Hurez VJ, Bahar R, Kious MJ, Livi CB, Wall SR, Chen L, Zhang B, Shin T, Curiel TJ. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. Journal of Immunology (Baltimore, Md. : 1950). 185: 2747-53. PMID 20686128 DOI: 10.4049/Jimmunol.1000496 |
0.378 |
|
| 2010 |
Tomihara K, Guo M, Shin T, Sun X, Ludwig SM, Brumlik MJ, Zhang B, Curiel TJ, Shin T. Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. Journal of Immunology (Baltimore, Md. : 1950). 184: 6151-60. PMID 20427766 DOI: 10.4049/Jimmunol.0903519 |
0.515 |
|
| 2010 |
Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Research. 70: 2245-55. PMID 20179192 DOI: 10.1158/0008-5472.Can-09-3109 |
0.738 |
|
| 2010 |
Daniel BJ, Pandeswara S, Brumlik MJ, Liu A, Thibodeaux SR, Ludwig SM, Sun X, Curiel TJ. A simple method to detect Toxoplasma gondii-specific cytotoxic T cells in vivo. Journal of Immunological Methods. 355: 86-90. PMID 20149795 DOI: 10.1016/J.Jim.2010.01.013 |
0.704 |
|
| 2009 |
Ruter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Frontiers in Bioscience (Landmark Edition). 14: 1761-70. PMID 19273160 DOI: 10.2741/3338 |
0.768 |
|
| 2008 |
Wei S, Curiel T, Coukos G, Liu R, Zou W. Inhibitory B7 family members in human ovarian carcinoma. Advances in Experimental Medicine and Biology. 622: 261-71. PMID 18546634 DOI: 10.1007/978-0-387-68969-2_21 |
0.481 |
|
| 2008 |
Barnett BG, Rüter J, Kryczek I, Brumlik MJ, Cheng PJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. Regulatory T cells: a new frontier in cancer immunotherapy. Advances in Experimental Medicine and Biology. 622: 255-60. PMID 18546633 DOI: 10.1007/978-0-387-68969-2_20 |
0.732 |
|
| 2008 |
Curiel TJ. Regulatory T cells and treatment of cancer. Current Opinion in Immunology. 20: 241-6. PMID 18508251 DOI: 10.1016/J.Coi.2008.04.008 |
0.501 |
|
| 2008 |
Brumlik MJ, Daniel BJ, Waehler R, Curiel DT, Giles FJ, Curiel TJ. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy Expert Opinion On Drug Delivery. 5: 87-103. PMID 18095930 DOI: 10.1517/17425247.5.1.87 |
0.673 |
|
| 2008 |
Wall S, Jeansonne D, Lin P, Liu A, Rennebeck G, Thibodeaux S, Livi C, Daniel B, Curiel T. 340 Effects of interferon-α on regulatory T-cell depletion in cancer immunotherapy Cytokine. 43: 324. DOI: 10.1016/J.Cyto.2008.07.424 |
0.46 |
|
| 2007 |
Wei S, Daniel BJ, Brumlik MJ, Burow ME, Zou W, Khan IA, Wadsworth S, Siekierka J, Curiel TJ. Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection. Antimicrobial Agents and Chemotherapy. 51: 4324-8. PMID 17923491 DOI: 10.1128/Aac.00680-07 |
0.693 |
|
| 2007 |
Tang Y, Zhao DY, Elliott S, Zhao W, Curiel TJ, Beckman BS, Burow ME. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. International Journal of Oncology. 31: 705-11. PMID 17786300 DOI: 10.3892/Ijo.31.4.705 |
0.399 |
|
| 2007 |
Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 110: 3192-201. PMID 17616639 DOI: 10.1182/Blood-2007-06-094615 |
0.424 |
|
| 2007 |
Curiel TJ. Tregs and rethinking cancer immunotherapy. The Journal of Clinical Investigation. 117: 1167-74. PMID 17476346 DOI: 10.1172/Jci31202 |
0.48 |
|
| 2007 |
Curiel TJ. Regulatory T-cell development: is Foxp3 the decider? Nature Medicine. 13: 250-3. PMID 17342117 DOI: 10.1038/Nm0307-250 |
0.386 |
|
| 2007 |
Rüter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. T-Regulatory Cell Manipulation in Tumor Immunotherapy Cancer Vaccines and Tumor Immunity. 189-204. DOI: 10.1002/9780470170113.ch12 |
0.711 |
|
| 2006 |
Barnett BG, Ruter J, Brumlik MJ, Kryczek I, Cheng PJ, Zou W, Curiel TJ. A phase II trial of denileukin diftitox to treat refractory advanced-stage ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2506. PMID 27954747 DOI: 10.1200/Jco.2006.24.18_Suppl.2506 |
0.443 |
|
| 2006 |
Salvo VA, Boué SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardt PW, Beckman BS, McLachlan JA, Cleveland TE, et al. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7159-64. PMID 17145841 DOI: 10.1158/1078-0432.Ccr-06-1426 |
0.354 |
|
| 2006 |
Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. The Journal of Experimental Medicine. 203: 871-81. PMID 16606666 DOI: 10.1084/Jem.20050930 |
0.394 |
|
| 2006 |
Rüter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. Manipulating T regulatory cells in cancer immunotherapy Expert Review of Dermatology. 1: 589-597. DOI: 10.1586/17469872.1.4.589 |
0.755 |
|
| 2006 |
curiel T, Barnett B, Zou W, Kryczek I, Brumlik M, Cheng J, Rueter J. 23 INVITED T regs in cancer European Journal of Cancer Supplements. 4: 11. DOI: 10.1016/S1359-6349(06)70028-3 |
0.429 |
|
| 2005 |
Wei S, Kryczek I, Zou L, Curiel T, Cheng P, Zou W. Novel tumor immunotherapy: Targeting dysfunctional antigen presenting cells. Discovery Medicine. 5: 489-92. PMID 20704848 |
0.373 |
|
| 2005 |
Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. American Journal of Reproductive Immunology (New York, N.Y. : 1989). 54: 369-77. PMID 16305662 DOI: 10.1111/J.1600-0897.2005.00330.X |
0.549 |
|
| 2005 |
Combe CL, Curiel TJ, Moretto MM, Khan IA. NK cells help to induce CD8(+)-T-cell immunity against Toxoplasma gondii in the absence of CD4(+) T cells. Infection and Immunity. 73: 4913-21. PMID 16041005 DOI: 10.1128/Iai.73.8.4913-4921.2005 |
0.428 |
|
| 2005 |
Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel T, Lange A, Zou W. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Research. 65: 5020-6. PMID 15958543 DOI: 10.1158/0008-5472.Can-04-4043 |
0.491 |
|
| 2005 |
Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, Curiel TJ, Douglas JT, Scheper RJ, Curiel DT. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biology & Therapy. 4: 289-94. PMID 15753654 DOI: 10.4161/Cbt.4.3.1499 |
0.32 |
|
| 2005 |
Brumlik MJ, Wei S, Lacey M, Curiel TJ. 304 TOXOPLASMA GONDII EXPRESSES TWO DISTINCT MITOGEN-ACTIVATED PROTEIN KINASE GENES THAT ARE DIFFERENTIALLY REGULATED Journal of Investigative Medicine. 53: S307.2-S307. DOI: 10.2310/6650.2005.00006.303 |
0.305 |
|
| 2005 |
Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. 290 DEPLETING REGULATORY T CELLS IS ASSOCIATED WITH IMPROVED IMMUNITY AND TUMOR CLEARANCE IN HUMAN CANCER Journal of Investigative Medicine. 53: S304.4-S304. DOI: 10.2310/6650.2005.00006.218 |
0.503 |
|
| 2005 |
Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. 219 DEPLETING REGULATORY T CELLS IS ASSOCIATED WITH IMPROVED IMMUNITY AND TUMOR CLEARANCE IN HUMAN CANCER Journal of Investigative Medicine. 53: S291.3-S291. DOI: 10.2310/6650.2005.00006.218 |
0.44 |
|
| 2004 |
Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, Wei S, David O, Curiel TJ, Zou W. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Research. 64: 8451-5. PMID 15548717 DOI: 10.1158/0008-5472.Can-04-1987 |
0.331 |
|
| 2004 |
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine. 10: 942-9. PMID 15322536 DOI: 10.1038/Nm1093 |
0.522 |
|
| 2004 |
Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Research. 64: 5535-8. PMID 15313886 DOI: 10.1158/0008-5472.Can-04-1272 |
0.403 |
|
| 2004 |
Weldon CB, Elliott S, Zhu Y, Clayton JL, Curiel TJ, Jaffe BM, Burow ME. Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators. Surgery. 136: 346-54. PMID 15300201 DOI: 10.1016/J.Surg.2004.05.010 |
0.307 |
|
| 2004 |
Curiel TJ, Morris C, Brumlik M, Landry SJ, Finstad K, Nelson A, Joshi V, Hawkins C, Alarez X, Lackner A, Mohamadzadeh M. Peptides identified through phage display direct immunogenic antigen to dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 172: 7425-31. PMID 15187120 DOI: 10.4049/Jimmunol.172.12.7425 |
0.376 |
|
| 2004 |
Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. International Journal of Oncology. 24: 1473-80. PMID 15138590 DOI: 10.3892/Ijo.24.6.1473 |
0.327 |
|
| 2004 |
Pulendran B, Dillon S, Joseph C, Curiel T, Banchereau J, Mohamadzadeh M. Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. European Journal of Immunology. 34: 66-73. PMID 14971031 DOI: 10.1002/Eji.200324567 |
0.358 |
|
| 2003 |
Kawakami Y, Curiel TJ, Curiel DT. Cancer gene therapy and immunotherapy. Cancer Chemotherapy and Biological Response Modifiers. 21: 327-37. PMID 15338753 DOI: 10.1016/S0921-4410(03)21016-4 |
0.32 |
|
| 2003 |
Knutson KL, Curiel TJ, Salazar L, Disis ML. Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematology/Oncology Clinics of North America. 17: 1051-73. PMID 12959191 DOI: 10.1016/S0889-8588(03)00064-9 |
0.395 |
|
| 2003 |
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Medicine. 9: 562-7. PMID 12704383 DOI: 10.1038/Nm863 |
0.422 |
|
| 2002 |
Wei S, Marches F, Borvak J, Zou W, Channon J, White M, Radke J, Cesbron-Delauw MF, Curiel TJ. Toxoplasma gondii-infected human myeloid dendritic cells induce T-lymphocyte dysfunction and contact-dependent apoptosis. Infection and Immunity. 70: 1750-60. PMID 11895936 DOI: 10.1128/Iai.70.4.1750-1760.2002 |
0.342 |
|
| 2002 |
Curiel TJ, Curiel DT. Tumor immunotherapy: inching toward the finish line. The Journal of Clinical Investigation. 109: 311-2. PMID 11827989 DOI: 10.1172/Jci15042 |
0.401 |
|
| 2001 |
Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T, Curiel DT, Galanaud P, Capron F, Emilie D, ... Curiel TJ, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Medicine. 7: 1339-46. PMID 11726975 DOI: 10.1038/Nm1201-1339 |
0.327 |
|
| 1998 |
Purner MB, Berens RL, Tomavo S, Lecordier L, Cesbron-Delauw MF, Kotzin BL, Curiel TJ. Stimulation of human T lymphocytes obtained from Toxoplasma gondii-seronegative persons by proteins derived from T. gondii. The Journal of Infectious Diseases. 177: 746-53. PMID 9498457 DOI: 10.1086/514216 |
0.322 |
|
| Show low-probability matches. |